Trial Profile
A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 08 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Feb 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 14 Feb 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2021.